Trials / Completed
CompletedNCT00192114
Enzastaurin for Patients With Metastatic Colorectal Cancer
A Phase 2 Study of Oral Enzastaurin HCl in Patients With Metastatic Colorectal Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
Enzastaurin given daily to participants with colorectal cancer who have Stage 4 disease and have not received prior chemotherapy for advanced colorectal cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enzastaurin HCl | 1200 milligrams (mg) loading dose orally, then 500 mg, orally, daily, up to six 28-day cycles. |
Timeline
- Start date
- 2005-08-01
- Primary completion
- 2008-03-01
- Completion
- 2008-03-01
- First posted
- 2005-09-19
- Last updated
- 2020-08-06
- Results posted
- 2020-08-06
Locations
3 sites across 2 countries: Denmark, Sweden
Source: ClinicalTrials.gov record NCT00192114. Inclusion in this directory is not an endorsement.